Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 5Unknown 2Not yet recruiting 2Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

pembrolizumab 55Carboplatin 33Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16130-nm albumin-bound paclitaxel 15Specimen Handling 14toripalimab 11Drug Therapy 11Magnetic Resonance Spectroscopy 10Biopsy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Injections × Clear all
NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3 Recruiting
364 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07208149 2026-02-12

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Shenzhen Majory Biotechnology Co., Ltd.

Phase 1/2 Recruiting
42 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Recruiting
220 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06220214 2026-01-15

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Recruiting
30 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
400 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡